Literature DB >> 21756205

Human papillomavirus: science and technologies for the elimination of cervical cancer.

F Xavier Bosch1.   

Abstract

INTRODUCTION: Academic research has made a significant advancement in understanding the viral causes of cervical cancer and generating the technology for prevention, both at the primary and secondary levels. Human papillomaviruses (HPVs) have been recognized as the first necessary cause of cervical cancer, the second most common cancer in women worldwide. AREAS COVERED: This paper reviews the epidemiological evidence of the causality of HPV in relation to cervical cancer, other genital tract cancers and some cancers of the oral cavity and oropharynx. The review also covers HPV DNA testing as a screening tool. DNA probes of high-risk HPV types in different formats have been fully validated as primary screening tests, as secondary triage tests and as a prognostic marker following treatment of high grade squamous intraepithelial lesions (HSIL). They consistently showed significant superiority over the conventional Pap smears. Biomarkers of the activation of oncogenes (HPV mRNA, p16 and other) are being tested as screening options to improve in sensitivity and specificity, with promising results. HPV vaccines against the two most common HPV types in cancer have completed their Phase III trials with excellent results in efficacy and safety. Combined strategies of HPV vaccination and HPV-based screening tests could theoretically control cervical cancer in any population in which a large coverage with both preventive options is ensured. Accessibility of developing countries to vaccination and low-cost HPV screening options are the barriers to overcome at present. EXPERT OPINION: This paper provides a synthesis of the evidence available supporting the novel paradigm for cervical cancer prevention that has reached a large consensus within the mainstream HPV and cervical cancer prevention research communities. The available technology for prevention and its developments allows real opportunities for cervical cancer elimination in defined populations to be foreseen.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21756205     DOI: 10.1517/14656566.2011.596527

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  13 in total

1.  Potential use of vaccines in the primary prevention of breast cancer in high-risk patients.

Authors:  Matteo Lazzeroni; Davide Serrano
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

2.  HPV vaccination and cervical cancer.

Authors:  Anne Szarewski
Journal:  Curr Oncol Rep       Date:  2012-12       Impact factor: 5.075

Review 3.  Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches.

Authors:  Davide Serrano; Matteo Lazzeroni; Bernardo Bonanni
Journal:  Mol Oncol       Date:  2014-12-20       Impact factor: 6.603

4.  Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.

Authors:  Syed Waqas Hassan; Mohammad Tahir Waheed; Martin Müller; Jihong Liu Clarke; Zabta Khan Shinwari; Andreas Günter Lössl
Journal:  Hum Vaccin Immunother       Date:  2014-11-19       Impact factor: 3.452

Review 5.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

Review 6.  Cervical cancer screening: A never-ending developing program.

Authors:  Ciro Comparetto; Franco Borruto
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

7.  Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study.

Authors:  Chia-Hung Kao; Li-Min Sun; Ji-An Liang; Shih-Ni Chang; Fung-Chang Sung; Chih-Hsin Muo
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

8.  Economic Evaluation of Screening Strategies Combined with HPV Vaccination of Preadolescent Girls for the Prevention of Cervical Cancer in Vientiane, Lao PDR.

Authors:  Phetsavanh Chanthavilay; Daniel Reinharz; Mayfong Mayxay; Keokedthong Phongsavan; Donald E Marsden; Lynne Moore; Lisa J White
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

9.  Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark.

Authors:  Jens Olsen; Tine Rikke Jørgensen; Kristian Kofoed; Helle Kiellberg Larsen
Journal:  BMC Public Health       Date:  2012-12-17       Impact factor: 3.295

Review 10.  Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV.

Authors:  Simona Di Mario; Vittorio Basevi; Pier Luigi Lopalco; Sara Balduzzi; Roberto D'Amico; Nicola Magrini
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.